Linagliptin Krka (Linagliptin) 5 mg
DPP-4 Inhibitor for Type 2 Diabetes Mellitus
Linagliptin Krka is a prescription medication containing linagliptin 5 mg, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in adults with type 2 diabetes mellitus to improve blood sugar control. It works by enhancing the body's natural incretin hormones, which stimulate insulin release and reduce glucagon secretion in a glucose-dependent manner. Linagliptin Krka is taken once daily, does not require dose adjustment for kidney or liver impairment, and is weight-neutral. It can be used alone or in combination with other diabetes medications.
Quick Facts
Key Takeaways
- Linagliptin Krka is a once-daily oral DPP-4 inhibitor used to lower blood sugar in adults with type 2 diabetes, either alone or with other diabetes medications.
- It is one of the few diabetes drugs that requires no dose adjustment for kidney or liver impairment, making it suitable for patients with renal disease.
- Linagliptin is weight-neutral and carries a low risk of hypoglycemia when used without sulfonylureas or insulin.
- The CARMELINA and CAROLINA trials demonstrated cardiovascular safety, confirming no increased risk of major cardiovascular events.
- Patients should be aware of the rare risk of acute pancreatitis and report persistent severe abdominal pain to their healthcare provider immediately.
What Is Linagliptin Krka and What Is It Used For?
Linagliptin Krka contains the active substance linagliptin, which belongs to a group of medicines called dipeptidyl peptidase-4 (DPP-4) inhibitors, also known as gliptins. These medications represent an important class of oral antidiabetic agents that have been widely used since the first DPP-4 inhibitor was approved in 2006. Linagliptin Krka is a generic version of the original linagliptin product and is manufactured by Krka, a well-established European pharmaceutical company.
Type 2 diabetes is a chronic metabolic condition characterized by insulin resistance and progressive beta-cell dysfunction, leading to elevated blood glucose levels. When diet and exercise alone are insufficient to achieve adequate glycemic control, pharmacological therapy becomes necessary. Linagliptin Krka is indicated for the treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control. It can be prescribed in several ways:
- Monotherapy: When metformin is inappropriate due to intolerance or contraindication (such as in patients with severe renal impairment where metformin is not recommended).
- Dual therapy: In combination with metformin, a sulfonylurea, a thiazolidinedione, or a sodium-glucose co-transporter 2 (SGLT2) inhibitor when these agents alone do not provide sufficient glycemic control.
- Triple therapy: In combination with metformin and a sulfonylurea, or metformin and insulin, when dual therapy fails to achieve target blood sugar levels.
- Add-on to insulin: Combined with insulin, with or without metformin, when insulin at a stable dose does not provide adequate glycemic control.
How Does Linagliptin Work?
Linagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). After you eat a meal, your gut releases incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a crucial role in blood sugar regulation by stimulating insulin release from the pancreatic beta cells and suppressing glucagon secretion from alpha cells. However, GLP-1 and GIP are rapidly degraded by the DPP-4 enzyme, typically within 1-2 minutes.
By blocking DPP-4, linagliptin allows these beneficial incretin hormones to remain active for a longer period, resulting in increased insulin secretion and decreased glucagon levels, both in a glucose-dependent manner. This glucose-dependent mechanism means that the drug primarily works when blood sugar levels are elevated, which significantly reduces the risk of hypoglycemia (low blood sugar) compared to some other diabetes medications such as sulfonylureas.
Clinical studies have demonstrated that linagliptin at the recommended dose of 5 mg once daily inhibits more than 80% of DPP-4 activity over a 24-hour period. In clinical trials, linagliptin reduced HbA1c (glycated hemoglobin, a measure of long-term blood sugar control) by approximately 0.5-0.7% when used as monotherapy, and by a similar amount when added to existing therapy. While this reduction may appear modest compared to some other diabetes medications, it is clinically meaningful and is achieved with a very favorable safety profile.
Unique Pharmacological Properties
Linagliptin has several pharmacological characteristics that distinguish it from other DPP-4 inhibitors. Most notably, it is primarily eliminated through the bile and gut via the enterohepatic system, with less than 5% excreted through the kidneys. This non-renal elimination pathway means that no dose adjustment is required in patients with any degree of renal impairment, including those on dialysis. This is a significant advantage, as chronic kidney disease is common in patients with type 2 diabetes and many other antidiabetic medications require dose reduction or are contraindicated in advanced renal disease.
Additionally, linagliptin has a very long terminal half-life of over 100 hours due to its strong binding to the DPP-4 enzyme in tissues. The effective accumulation half-life is approximately 12 hours, supporting once-daily dosing. The drug reaches steady-state plasma concentrations after three days of repeated dosing. Linagliptin does not undergo significant metabolism by cytochrome P450 enzymes, which reduces the potential for drug-drug interactions.
What Should You Know Before Taking Linagliptin Krka?
Contraindications
Linagliptin Krka must not be used if you are allergic (hypersensitive) to linagliptin or any of the other ingredients in the tablet. Serious hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative skin conditions, have been reported in post-marketing surveillance with DPP-4 inhibitors, although these events are rare. If you experience signs of a serious allergic reaction such as swelling of the face, lips, tongue, or throat, difficulty breathing, or severe skin rash, seek medical attention immediately and discontinue the medication.
Linagliptin Krka is not indicated for the treatment of type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. It should not be used as a substitute for insulin in patients who require insulin therapy. The drug has only been studied and approved for use in adults aged 18 years and older; its safety and efficacy in children and adolescents under 18 have not been established.
Warnings and Precautions
Cases of acute pancreatitis have been reported with DPP-4 inhibitors, including linagliptin. Patients should be informed about the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain, often radiating to the back, that may be accompanied by nausea and vomiting. If pancreatitis is suspected, Linagliptin Krka should be discontinued immediately. If acute pancreatitis is confirmed, treatment should not be restarted. Caution should be exercised in patients with a history of pancreatitis.
Hypoglycemia risk with concomitant medications: When linagliptin is used in combination with a sulfonylurea (such as glimepiride or glibenclamide) or insulin, the risk of hypoglycemia is increased. Your doctor may need to reduce the dose of the sulfonylurea or insulin when adding linagliptin to prevent episodes of low blood sugar. Signs of hypoglycemia include trembling, sweating, rapid heartbeat, hunger, dizziness, and confusion.
Heart failure: Clinical trials with DPP-4 inhibitors as a class have raised questions about a potential association with heart failure hospitalization. The CARMELINA trial, which specifically studied linagliptin, did not demonstrate an increased risk of heart failure hospitalization compared to placebo. However, experience in patients with New York Heart Association (NYHA) functional class III-IV heart failure is limited, and caution is advised in these patients.
Bullous pemphigoid: Post-marketing reports of bullous pemphigoid (a rare blistering skin condition) requiring hospitalization have been associated with DPP-4 inhibitor use. If bullous pemphigoid is suspected, linagliptin should be discontinued. Patients should promptly report the development of blisters or erosions to their healthcare provider.
Surgery and illness: During periods of significant physiological stress such as major surgery, serious illness, or trauma, temporary insulin therapy may be required regardless of current diabetes treatment. Your doctor will advise you on when to temporarily switch to insulin and when it is appropriate to resume linagliptin.
Pregnancy and Breastfeeding
There is limited data on the use of linagliptin in pregnant women. Animal studies have not indicated direct or indirect harmful effects on reproductive toxicity. However, as a precautionary measure, Linagliptin Krka should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential who are not using contraception should discuss their pregnancy plans with their doctor before starting treatment.
It is not known whether linagliptin is excreted in human breast milk. Animal studies have shown excretion of linagliptin in milk. A risk to the breastfed infant cannot be excluded, and therefore a decision must be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If you are breastfeeding or plan to breastfeed, consult your healthcare provider before taking this medication.
Fertility: No studies on the effect of linagliptin on human fertility have been conducted. Pre-clinical animal studies did not indicate direct or indirect harmful effects on fertility at the recommended human dose.
How Does Linagliptin Krka Interact with Other Drugs?
One of the advantages of linagliptin compared to some other diabetes medications is its relatively low potential for pharmacokinetic drug interactions. Linagliptin is primarily a substrate of P-glycoprotein (P-gp) and is not a significant substrate, inhibitor, or inducer of cytochrome P450 (CYP) enzymes. In vitro studies have shown that linagliptin is a weak competitive inhibitor of CYP3A4 and a weak-to-moderate mechanism-based inhibitor, but these effects are not considered clinically relevant at therapeutic doses.
However, certain medications can affect linagliptin levels or interact pharmacodynamically. It is always important to inform your doctor and pharmacist about all medicines you are taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins.
Major Interactions
| Drug | Effect | Clinical Recommendation |
|---|---|---|
| Rifampicin | Strong P-gp and CYP3A4 inducer. Reduces linagliptin exposure (AUC) by approximately 40%, potentially decreasing efficacy of DPP-4 inhibition below the therapeutic threshold. | Combination is not recommended. The efficacy of linagliptin may be reduced. Consider alternative diabetes treatment if rifampicin is required. |
| Sulfonylureas (glimepiride, glibenclamide, glipizide) | Pharmacodynamic interaction. Both drug classes lower blood glucose, resulting in additive hypoglycemic effects. | A lower dose of sulfonylurea may be needed to reduce hypoglycemia risk. Monitor blood glucose closely when initiating or adjusting treatment. |
| Insulin | Pharmacodynamic interaction. Additive blood glucose-lowering effect increases the risk of hypoglycemia. | A lower dose of insulin may be necessary. Increase frequency of blood glucose monitoring, especially during the initial combination period. |
Minor Interactions and No Significant Interactions
| Drug | Study Finding | Clinical Recommendation |
|---|---|---|
| Metformin | No clinically relevant change in pharmacokinetics of either drug when co-administered. | No dose adjustment required. Commonly prescribed combination. |
| Ritonavir | Strong CYP3A4 and P-gp inhibitor. Increases linagliptin exposure (AUC) by approximately 2-fold. | No dose adjustment is needed as the increased exposure is not expected to be clinically relevant at the 5 mg dose. |
| Digoxin | No clinically meaningful change in digoxin pharmacokinetics when co-administered with linagliptin. | No dose adjustment required for either drug. |
| Warfarin | Linagliptin does not alter the pharmacokinetics or pharmacodynamics of warfarin (S-warfarin or R-warfarin). | No dose adjustment or additional INR monitoring required beyond routine clinical practice. |
| Oral contraceptives | Linagliptin does not alter the pharmacokinetics of levonorgestrel or ethinylestradiol. | No dose adjustment required. Contraceptive efficacy is not affected. |
| Pioglitazone | No clinically relevant pharmacokinetic interaction between linagliptin and pioglitazone. | No dose adjustment required for either drug. |
Other strong P-glycoprotein inducers besides rifampicin (such as carbamazepine, phenobarbital, phenytoin, and St. John's Wort) may also reduce the efficacy of linagliptin. If these medications are necessary, your doctor may need to consider alternative diabetes treatment or monitor your blood glucose more closely.
What Is the Correct Dosage of Linagliptin Krka?
Linagliptin Krka has a simple and straightforward dosing regimen that applies to nearly all adult patients, regardless of their renal or hepatic function. This ease of dosing is one of the clinical advantages of linagliptin over some other DPP-4 inhibitors and antidiabetic medications that require dose titration or dose adjustment based on organ function.
Adults
Standard Adult Dose
The recommended dose of Linagliptin Krka is 5 mg once daily. The tablet should be swallowed whole with water. It can be taken at any time of day, with or without food. There is no need to titrate the dose. This dose applies whether linagliptin is used as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, or insulin.
If you are adding linagliptin to existing therapy with a sulfonylurea or insulin, your doctor may reduce the dose of the sulfonylurea or insulin to lower the risk of hypoglycemia. Linagliptin can be taken regardless of mealtimes, which provides flexibility in daily scheduling. However, it is best to take the tablet at approximately the same time each day to help establish a routine.
Children and Adolescents
Pediatric Use
Linagliptin Krka is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of linagliptin in this population have not been established, and no data are available. Type 2 diabetes in children and adolescents should be managed according to pediatric-specific guidelines.
Elderly Patients
Elderly (65 years and older)
No dose adjustment is required in elderly patients. Clinical trials included a substantial number of patients aged 65 and older, and no clinically relevant differences in efficacy or safety were observed compared to younger adults. The CARMELINA trial enrolled a large proportion of elderly patients, further supporting the safety of linagliptin in this age group. However, as with all diabetes medications in elderly patients, careful monitoring for hypoglycemia is recommended, particularly when used in combination with sulfonylureas or insulin.
Renal impairment: No dose adjustment is required for patients with any degree of renal impairment, including those with end-stage renal disease requiring dialysis. This is because linagliptin is primarily eliminated through non-renal pathways (bile and gut), with less than 5% of the administered dose excreted by the kidneys.
Hepatic impairment: No dose adjustment is required for patients with mild, moderate, or severe hepatic impairment based on pharmacokinetic studies. However, clinical experience in patients with severe hepatic impairment is limited.
Missed Dose
If you forget to take a dose of Linagliptin Krka, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a forgotten dose. If you are unsure about what to do, contact your pharmacist or doctor for advice.
Overdose
In clinical trials, single doses of up to 600 mg linagliptin (120 times the recommended dose) were administered to healthy subjects and were well tolerated. There is no experience with doses above 600 mg. In the event of an overdose, supportive measures should be employed as dictated by the patient's clinical status. Linagliptin is not expected to be significantly removed by hemodialysis or peritoneal dialysis due to its high protein binding and extensive tissue distribution. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately.
What Are the Side Effects of Linagliptin Krka?
Like all medicines, Linagliptin Krka can cause side effects, although not everybody gets them. The overall safety profile of linagliptin has been established through extensive clinical trials involving more than 14,000 patients, as well as through post-marketing surveillance since its initial approval. Linagliptin is generally considered to have a favorable safety profile within the DPP-4 inhibitor class. In placebo-controlled clinical trials, the overall incidence of adverse events was similar between linagliptin-treated patients and those receiving placebo, except for a slightly higher rate of hypoglycemia when linagliptin was combined with sulfonylureas or insulin.
The following side effects have been reported with linagliptin, organized by frequency according to the following convention: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), and rare (may affect up to 1 in 1,000 people).
Common
- Nasopharyngitis (runny nose, sore throat, common cold symptoms)
- Cough
- Hypoglycemia (low blood sugar) — when used with sulfonylurea or insulin
- Increased blood lipase levels (usually without clinical symptoms)
Uncommon
- Acute pancreatitis (severe abdominal pain radiating to the back, nausea, vomiting)
- Hypersensitivity reactions (rash, urticaria/hives, angioedema)
- Constipation
- Increased blood amylase levels
- Mouth ulceration (stomatitis)
Rare
- Bullous pemphigoid (blistering skin condition)
- Anaphylaxis (severe life-threatening allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Exfoliative skin conditions (severe peeling skin reactions)
- Rhabdomyolysis (breakdown of muscle tissue)
Stop taking Linagliptin Krka and seek emergency medical help if you experience: severe, persistent abdominal pain that may radiate to the back (possible pancreatitis); swelling of the face, lips, tongue, or throat with difficulty breathing (possible anaphylaxis or angioedema); widespread blistering of the skin (possible bullous pemphigoid); or signs of severe allergic reaction including generalized rash and difficulty breathing.
Cardiovascular Safety
An important consideration for any diabetes medication is its cardiovascular safety. Linagliptin has been evaluated in two major cardiovascular outcome trials:
- CARMELINA (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin): This large randomized trial enrolled 6,979 patients with type 2 diabetes and high cardiovascular and renal risk. Linagliptin was non-inferior to placebo for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (hazard ratio 1.02, 95% CI 0.89-1.17). Importantly, there was no increased risk of heart failure hospitalization.
- CAROLINA (Cardiovascular Outcome Study of Linagliptin vs Glimepiride in Type 2 Diabetes): This active-comparator trial compared linagliptin to the sulfonylurea glimepiride in 6,033 patients. Linagliptin was non-inferior to glimepiride for cardiovascular events, but with significantly fewer hypoglycemic events and no weight gain, supporting its favorable benefit-risk profile.
Long-Term Safety
Long-term safety data for linagliptin extend beyond 4 years in clinical trial settings. No new safety signals have emerged with prolonged use. The incidence of infections, liver enzyme elevations, and skin disorders was comparable between linagliptin and placebo groups. There has been no evidence of increased risk of malignancies, thyroid disorders, or immunological adverse effects. Weight remained stable during long-term treatment, confirming the weight-neutral profile of linagliptin.
How Should You Store Linagliptin Krka?
Proper storage of medication is essential to maintain its effectiveness and safety throughout its shelf life. Linagliptin Krka tablets should be stored according to the following guidelines:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze the tablets.
- Moisture protection: Store in the original blister packaging to protect from moisture. The blister packaging is designed to provide a moisture barrier that maintains the stability of the film-coated tablet.
- Children: Keep this medicine out of the sight and reach of children. Store in a secure location, ideally in a high or locked cabinet.
- Expiry date: Do not use this medicine after the expiry date stated on the blister and the carton after "EXP." The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.
If you notice any visible changes in the appearance of the tablets (such as discoloration, crumbling, or unusual odor), do not take the medication and consult your pharmacist. Always check the expiry date before taking any dose, particularly if you have had the medication for an extended period.
What Does Linagliptin Krka Contain?
Active Ingredient
Each film-coated tablet contains 5 mg linagliptin. Linagliptin is a xanthine-based compound with the chemical name (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione. It has a molecular weight of 472.54 g/mol and acts as a selective, competitive, reversible inhibitor of the DPP-4 enzyme.
Inactive Ingredients (Excipients)
The inactive ingredients in the tablet core and film coating serve various pharmaceutical functions, including binding, filling, facilitating disintegration, and providing a protective coating. The complete list of excipients includes:
Tablet core:
- Mannitol (E421) — filler/bulking agent
- Pregelatinised starch — binder and disintegrant
- Maize starch — filler and disintegrant
- Copovidone — binder
- Magnesium stearate — lubricant
Film coating:
- Hypromellose — film-forming agent
- Titanium dioxide (E171) — opacifier and colorant
- Talc — anti-adherent
- Iron oxide red (E172) — colorant
Tablet appearance: Linagliptin Krka 5 mg tablets are light pink, round, biconvex film-coated tablets. They may be debossed with an identification marking depending on the batch. Each tablet is packaged in a moisture-protective blister.
Linagliptin Krka tablets do not contain lactose, gluten, sucrose, or any animal-derived ingredients. If you have known allergies to any of the listed excipients, particularly mannitol or colorants (titanium dioxide, iron oxide), inform your doctor or pharmacist before starting treatment.
Frequently Asked Questions About Linagliptin Krka
Linagliptin Krka is a prescription medication used to treat type 2 diabetes mellitus in adults. It contains linagliptin 5 mg, a DPP-4 inhibitor that helps lower blood sugar levels. It is used alongside diet and exercise, either as monotherapy when metformin is not tolerated, or in combination with other diabetes medications including metformin, sulfonylureas, or insulin. It is not intended for type 1 diabetes or diabetic ketoacidosis.
Linagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme normally breaks down incretin hormones (GLP-1 and GIP) that are released after eating. By blocking DPP-4, linagliptin allows these hormones to remain active longer, which stimulates insulin release in a glucose-dependent manner and suppresses glucagon secretion, resulting in lower blood sugar levels without causing hypoglycemia when used alone.
Linagliptin Krka is considered weight-neutral, meaning it generally does not cause significant weight gain or weight loss. Clinical trials have shown that body weight remains relatively stable during treatment. This is an advantage compared to some other diabetes medications, such as sulfonylureas or insulin, which are often associated with weight gain. The weight-neutral profile makes linagliptin suitable for patients who are concerned about weight management as part of their diabetes care.
Yes, Linagliptin Krka is one of the few diabetes medications that does not require dose adjustment in patients with any degree of renal impairment, including those with end-stage renal disease on dialysis. This is because linagliptin is primarily eliminated via the bile and gut rather than the kidneys, with less than 5% of the drug excreted renally. The CARMELINA trial specifically enrolled many patients with chronic kidney disease and confirmed the safety and efficacy of linagliptin in this population.
Linagliptin Krka and Trajenta both contain the same active ingredient, linagliptin 5 mg, and work in exactly the same way. Linagliptin Krka is a generic version manufactured by Krka, while Trajenta is the original brand-name product by Boehringer Ingelheim. Generic medications in the EU and other regulated markets must demonstrate bioequivalence and meet the same strict quality, safety, and efficacy standards as the original brand. The main difference is typically the cost, with generics being more affordable.
Acute pancreatitis has been reported as an uncommon side effect in patients taking linagliptin and other DPP-4 inhibitors. In the large CARMELINA trial, the incidence of pancreatitis was similar between linagliptin and placebo groups. Patients should be aware of the symptoms of acute pancreatitis, which include persistent, severe abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If pancreatitis is suspected, treatment should be discontinued immediately. Patients with a history of pancreatitis should discuss the risks with their doctor.
References and Medical Sources
This article is based on evidence from the following peer-reviewed sources and international guidelines. All medical claims are supported by Level 1A evidence where available.
- European Medicines Agency (EMA). Linagliptin Summary of Product Characteristics (SmPC). Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Tradjenta (linagliptin) tablets Prescribing Information. Last revised 2024. Available at: www.fda.gov
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Supplement 1).
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.
- British National Formulary (BNF). Linagliptin monograph. NICE. Available at: bnf.nice.org.uk
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of healthcare professionals with expertise in endocrinology, clinical pharmacology, and diabetes care. Our team includes board-certified physicians, clinical pharmacists, and medical writers who follow evidence-based medicine principles and international guidelines.
All content is reviewed by board-certified physicians specializing in endocrinology and clinical pharmacology. Our review process follows the GRADE evidence framework and adheres to WHO, EMA, FDA, and ADA/EASD guidelines.
We maintain strict editorial independence with no pharmaceutical company sponsorship or commercial funding. All medical claims are verified against peer-reviewed literature and updated in accordance with new evidence. Read our Editorial Standards.
Last medically reviewed: | Published: